These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 17618103

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S, Souza R, Jais X, Fadel E, Ali RH, Humbert M, Dartevelle P, Simonneau G, Sitbon O.
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [Abstract] [Full Text] [Related]

  • 3. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?
    Madden BP, Sheth A, Wilde M, Ong YE.
    Vascul Pharmacol; 2007 Apr; 47(2-3):184-8. PubMed ID: 17627899
    [Abstract] [Full Text] [Related]

  • 4. Chronic oral sildenafil therapy in severe pulmonary artery hypertension.
    Kothari SS, Duggal B.
    Indian Heart J; 2002 Apr; 54(4):404-9. PubMed ID: 12462669
    [Abstract] [Full Text] [Related]

  • 5. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.
    Jais X, Launay D, Yaici A, Le Pavec J, Tchérakian C, Sitbon O, Simonneau G, Humbert M.
    Arthritis Rheum; 2008 Feb; 58(2):521-31. PubMed ID: 18240255
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Clinical interpretation for the pressure-flow relationships in extrinsic allergic alveolitis and in interstitial lung disease pulmonary hypertension patients. Should we care for the lung, the pulmonary artery pressure or both?].
    Lupi-Herrera E, Santos-Martínez LE, Pulido T, Sandoval J.
    Arch Cardiol Mex; 2009 Feb; 79(2):91-103. PubMed ID: 19722378
    [Abstract] [Full Text] [Related]

  • 8. Aerosolized iloprost in CREST syndrome related pulmonary hypertension.
    Launay D, Hachulla E, Hatron PY, Goullard L, Onimus T, Robin S, Fauchais AL, Queyrel V, Michon-Pasturel U, Hebbar M, Saulnier F, Devulder B.
    J Rheumatol; 2001 Oct; 28(10):2252-6. PubMed ID: 11669165
    [Abstract] [Full Text] [Related]

  • 9. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension.
    Sastry BK, Narasimhan C, Reddy NK, Anand B, Prakash GS, Raju PR, Kumar DN.
    Indian Heart J; 2002 Oct; 54(4):410-4. PubMed ID: 12462670
    [Abstract] [Full Text] [Related]

  • 10. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?
    Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J.
    J Heart Lung Transplant; 2008 Mar; 27(3):329-34. PubMed ID: 18342757
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W, Boonstra A, Brand M, Rosenberg DM, Schaaf B, Postmus PE, Vonk Noordegraaf A.
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [Abstract] [Full Text] [Related]

  • 13. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
    Kotlyar E, Sy R, Keogh AM, Kermeen F, Macdonald PS, Hayward CS, McNeil KD, Celermajer DS.
    Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
    [Abstract] [Full Text] [Related]

  • 14. Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?
    Chapman TH, Wilde M, Sheth A, Madden BP.
    Vascul Pharmacol; 2009 Jun; 51(2-3):90-5. PubMed ID: 19386283
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.
    Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Hervé P, Simonneau G.
    Circulation; 2005 Jun 14; 111(23):3105-11. PubMed ID: 15939821
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension.
    Pérez-Peñate GM, Juliá-Serdà G, Ojeda-Betancort N, García-Quintana A, Pulido-Duque J, Rodríguez-Pérez A, Cabrera-Navarro P, Gómez-Sánchez MA.
    J Heart Lung Transplant; 2008 Dec 14; 27(12):1326-32. PubMed ID: 19059113
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.